# Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

> **NCT05521880** · PHASE4 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 2 (actual)

## Conditions studied

- Substance Use Disorders
- Infection, Soft Tissue
- Bacteremia
- Osteomyelitis Acute
- Septic Arthritis

## Interventions

- **DRUG:** Oritavancin

## Key facts

- **NCT ID:** NCT05521880
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-07-15
- **Primary completion:** 2025-05-22
- **Final completion:** 2025-05-23
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was not able to enroll adequate participants within predetermined timelines
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05521880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05521880, "Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT05521880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*